PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Merck signs next-gen RNA collab with Orna Therapeutics

Merck (MSD) and biotech startup Orna Therapeutics unveiled a collaboration agreement to discover, develop and commercialize multiple programs, including vaccines and therapeutics for infectious diseases and oncology, using Orna’s proprietary oRNA technology.

Merck will make an upfront payment of $150 million. In addition, Massachusetts-based Orna will be eligible to receive up to $3.5 billion in milestones associated with the progress of the multiple vaccine and therapeutic programs, as well as royalties on any approved products derived from the collaboration.

Per the deal, Orna will retain rights to its oRNA-LNP technology platform and will continue to advance other wholly owned programs in areas such as oncology and genetic disease. The company’s proprietary oRNA technology creates circular RNAs from linear RNAs by self-circularization. According to Orna, oRNA molecules have been shown to have greater stability in vivo than traditional linear mRNA and have the potential to produce larger quantities of therapeutic proteins inside the body. Newly synthesized oRNA molecules are more compactly packaged into custom lipid nanoparticles, which Orna has engineered to target key tissues in the body.

At the same time, Orna announced the initial closing of its $221 million Series B financing, featuring Merck as a new investor. Merck will also invest $100 million of equity alongside commitments from founding investors MPM Capital and BioImpact Capital.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026